Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Webcasts|April 15, 2024

Seek Out Your Best-Behaving ADC With Uncle and Stunner

Webinar Date/Time: Tue, May 7, 2024 11:00 AM EDT

Join this webinar to see how the Unchained Lab’s solutions quantitate ADCs, figure out their DAR, check for aggregation.

Register Free: https://www.biopharminternational.com/bp_w/best-behaving-ADC

Event Overview:

Antibody conjugates are powerful drugs, but they tend to aggregate and are always in short supply. Unchained Labs provides the right tools for ADC characterization: low-volume, high-throughput, integrated solutions that make it easy to scope out any biologic, even ADCs. Join this webinar to see how Unchained Lab's solutions quantitate ADCs, figure out their DAR, check for aggregation, conformational and colloidal stability to eventually help develop optimal formulation conditions.


Key Learning Objectives:

  • Determine quantity, DAR, and aggregation in an ADC preparation with Stunner.
  • Scrutinize conformational and colloidal stability of an ADC with Uncle.
  • Scope out formulation conditions and excipients to optimize stability of an ADC with Uncle.

Who Should Attend:

  • Chief Scientific Officers of companies working with biologics
  • VPs of Drug Discovery and Protein Sciences
  • Research Directors and Principal Scientists of Protein Sciences and Analytical Development
  • Formulation and Preformulation Scientists working with biologics


Speaker:

Andre Mueller, PhD
Marketing Manager, Biologics
Unchained Labs

Andre is Marketing Manager at Unchained Labs and supports the development of new biologic drugs. His expertise covers fluorescence, static light scattering, and dynamic light scattering for biophysical characterization of proteins and viral vectors. His research experience spans structural biology to plant physiology and across labs in Germany, Sweden, Denmark, and the USA. Andre earned his PhD at the Carlsberg Laboratory and had a post-doc appointment at Stanford University.


Register Free: https://www.biopharminternational.com/bp_w/best-behaving-ADC


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.